CLEO Network
@cleonetwork
Canadian Network for Learning Healthcare Systems and Cost-Effective ‘Omics Innovation (CLEO). #RegulatoryScienceLab
ID: 1205640617918754817
14-12-2019 00:08:34
315 Tweet
272 Followers
378 Following
Listening to the last session’s panelists share their thoughts on the evolution of data capture & sharing and how that is shifting culture in research. Ian Watson Lab Darrin Park Adrian Thorogood Lincoln Stein Melissa Coombs
Calling all Canadian researchers! The Marathon of Hope Cancer Centres Network has funding opportunities for projects addressing 6 key themes identified by its Patient Working Group . Approved projets will support research studies that centre patients, caregivers, and survivors and their needs as it
Great to see Prof. Boehler from TH Köln use the life-cycle HTA framework by Dean Regier Deirdre Weymann Sam Pollard et al. as a proposed way forward in addressing evidentiary challenges in precision oncology. #HTAi2024 nature.com/articles/s4169…
Emanuel Krebs presenting on target trial emulation #RWE for precision oncology reimbursement Deirdre Weymann CLEO Network #RegulatoryScienceLab #HTAi2024
New publication in Nature Medicine Exploring the benefits, harms and costs of genomic newborn screening for rare diseases With Exeter Rare Disease Richard Scott Prof Zornitza Stark & many others (see next tweet) nature.com/articles/s4159… QMUL Centre for Evaluation and Methods QMUL Centre for Evaluation and Methods Wolfson Institute of Population Health #healtheconomics
In this study, receiving a genetic diagnosis was not associated with cost savings. This finding suggests that patient benefit and cost-effectiveness should drive GWS implementation. ja.ma/3zDWIgw Deirdre Weymann John Buckell James Buchanan Dean Regier
Exciting day!! Our GenomeBC funded study examining changes in healthcare costs after GWS for children with rare diseases was just published! CLEO Network SFU Health Sciences UBC's School of Population and Public Health BC Cancer #RegulatoryScienceLab
"...genome-wide sequencing was not associated with changes in health care or diagnostic costs." Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases jamanetwork.com/journals/jaman… by Deirdre Weymann Dean Regier et al. BC Cancer GenomeBC et al.
In this study, receiving a genetic diagnosis was not associated with cost savings. This finding suggests that patient benefit and cost-effectiveness should drive GWS implementation. ja.ma/3XZXyOx Deirdre Weymann John Buckell James Buchanan Dean Regier
In this study, receiving a genetic diagnosis was not associated with cost savings. This finding suggests that patient benefit and cost-effectiveness should drive GWS implementation. ja.ma/4cbzg81 Deirdre Weymann John Buckell James Buchanan Dean Regier
Delighted to have our cost-effectiveness analysis of assay-guided treatment sequencing for CLL published in Scientific Reports! Thank you to my co-authors including Adam Raymakers Brandon Chan Alina Gerrie and Dean Regier! BC Cancer CLEO Network Link here: rb.gy/u64suy
So exciting to see this pan-Canadian CLEO Network research published! Patient perspectives are critical for informing precision oncology data sharing. BC Cancer UBC's School of Population and Public Health SFU Health Sciences #RegulatoryScienceLab
Exciting day!! Our new #RegulatoryScienceLab paper proposing multiple imputation for addressing immortal time bias in #precisionmedicine studies just came out in #HSR: onlinelibrary.wiley.com/doi/full/10.11… Huge thank you to my co-authors Emanuel Krebs & Dean Regier